Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Original Article
T.K. Choueiri, T. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Zurawski, E.Y. Ruiz, M. Maruzzo, A.S. Zaizar, L.E. Fein, F.A. Schutz, D.Y. Heng, F. Wang, F. Mataveli, Y.-L. Chang, M.v.K. Losio, C. Suarez, and R.J. Motzer
N Engl J Med 2023;388:1767-1778
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation